QN-302 downregulates S100P, a potential marker and therapeutic target in pancreatic cancer
March 15, 2023
A new experimental drug, QN-302, has shown high antiproliferative activity in pancreatic cancer cells and antitumor activity in experimental pancreatic cancer models.
